Full-Time

Corporate Counsel

US Market Access Legal

Confirmed live in the last 24 hours

Deadline 9/9/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

Compensation Overview

$125.3k - $208.8k/yr

Senior

Cambridge, MA, USA + 2 more

More locations: Washington, DC, USA | Morristown, NJ, USA

Candidates must be based in one of the specified locations: MA, NJ, or DC.

Category
Legal
Risk & Compliance
Legal & Compliance
Required Skills
Sales
Requirements
  • Juris Doctor (JD) degree from a highly respected, accredited law school
  • Minimum 5 years of prior experience at a law firm and/or in-house legal department, preferably in the healthcare, pharmaceutical, biotechnology, or medical device industry
  • Licensed to practice law and in good standing in at least one US jurisdiction (MA, NJ, or DC preferred)
  • Pharmaceutical industry experience, either in-house or through private practice
  • Substantive working knowledge of US Federal and state laws and regulations relating to the pharmaceutical industry, including the Anti-Kickback Statute and competition laws
  • Strong understanding of the US health care system and payer landscape
  • Experience with pharmaceutical discounting, pricing, contracting and sales matters
  • Ability to provide and effectively communicate sound legal advice coupled with a strong understanding of business needs
  • Comfortable engaging in proactive counseling and thoughtful risk-taking
  • Ability to be decisive, especially in ambiguous situations
  • Demonstrated excellence in understanding and digesting complex scenarios in order to identify and evaluate relevant issues and risks, propose solutions that take into consideration the relevant business objectives, and communicate those issues, risks, and solutions clearly and concisely to lawyers and non-lawyers alike
  • Team player with strong interpersonal skills and ability to work collaboratively, with a solution-oriented approach, in teams within legal, business, and functional areas
  • Experience covering an array of topic areas and adapting to new subject matter rapidly
  • Self-motivated, able to work independently, reliable, responsive, and accountable
Responsibilities
  • Serve as legal business partner to the US Market Access organization, providing pragmatic, solutions-oriented, proactive counseling in the development and execution of commercial strategies for commercialization of pharmaceutical products
  • Advise on the market access and launch strategy related to Sanofi’s pipeline products
  • Advise market access business partners on rebate and price concession strategies, government pricing, policy development, copay and patient assistance programs, government pricing, risk mitigation, and interactions with customers
  • Draft, negotiate and review market access-related agreements, including: PBM agreements, GPO agreements, Specialty Pharmacy agreements, wholesaler agreements, discount and rebate agreements, distribution agreements, innovative/value-based agreements, vendor agreements, and services agreements
  • Act as legal representative on US-based cross-functional Specialty Pricing Review Boards and Pricing Committees
  • Engage with commercial partners in a broad range of areas outside of market access such as sales, medical, regulatory, operations, finance, supply chain, manufacturing, pharmacovigilance, external/corporate affairs and other functions
  • Collaborate with other Legal, Ethics and Business Integrity colleagues to provide legal support to the organization
  • Develop and conduct training for internal teams on compliance and policy development topics related to commercial programs and interactions with customers
  • Ensure that client operations comply with applicable laws and company policies, including Anti-kickback Statute and other US healthcare compliance laws and regulations, antitrust, and FDA requirements
  • Analyze market access initiatives, advisory board proposals, and market access field-based activities for fraud and abuse, FDA, and other regulatory compliance
  • Ensure that business partners are kept abreast of all relevant legal developments in their areas of responsibility by providing training and periodic updates

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments worldwide. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse product pipeline and adapt to different regulatory environments. The company's goal is to enhance health outcomes and improve the quality of life for people globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's Q1 2025 profit grew by 20%, indicating strong financial performance.
  • The integration of AI in R&D accelerates drug discovery and reduces costs.
  • mRNA technology expansion offers new drug development opportunities for Sanofi.

What critics are saying

  • Increased competition in immunology may impact Sanofi's market share.
  • Potential regulatory delays could affect the launch of new drugs like tolebrutinib.
  • Acquisitions may lead to integration challenges and operational disruptions.

What makes Sanofi unique

  • Sanofi's acquisition of Blueprint Medicines expands its rare immunological disease portfolio.
  • The on-body injector for Sarclisa offers a novel delivery method for multiple myeloma.
  • Dupixent's approval for chronic spontaneous urticaria marks a significant therapeutic advancement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Sanofi
Jun 18th, 2025
Press release: Sanofi successfully prices €1.5 billion bond issue

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:  €750...

PharmiWeb
Jun 3rd, 2025
Asco: New Sarclisa Data Support Subcutaneous Administration With On-Body Injector

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

Sanofi
May 23rd, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...

Quantis
Apr 24th, 2025
Innate Pharma: €15M Investment by Sanofi

Innate Pharma announced a €15M investment by Sanofi, subscribing to 8,345,387 new shares at €1.7974 each. This capital increase supports their ongoing partnership, including the BCMA targeting ANKET® program. The investment will aid in extending Innate's cash runway for pipeline execution. The capital increase is expected to close on April 25, 2025, with shares trading on Euronext Paris the same day.